Zacks.com on MSN2d
AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH StudyShares of Akero Therapeutics AKRO skyrocketed 105.7% in a week after the company announced initial positive top line 96-week ...
Shares of Novo Nordisk NVO gained 8.5% on Friday after the company announced positive top-line data from an early to ...
Amycretin could give Novo a buzzy product in a newly competitive obesity market. It works similarly to existing GLP-1 ...
Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly ...
Novo Nordisk stock falls as Medicare selects its marketed semaglutide medicines catering to T2D and obesity for price ...
WASHINGTON (AP) — Popular weight loss and diabetes drugs like Ozempic and Wegovy have been added to ... “Some folks have to skip a dose in their prescription so they can make a prescription ...
Patients who took triple the normal dose of semaglutide, the main ingredient in Wegovy, for 72 weeks lost 20.7% of their body weight, Novo said Friday in a statement . That compared with a 17.5% ...
(AP Photo/David J. Phillip, File) A dosage of Wegovy, March 1, 2024 in Front Royal, Va. (AP Photo/Amanda Andrade-Rhoades, File) A Medicare card is seen on Monday, June 10, 2024, in Portland, Ore. (AP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback